Gilman Hill Asset Management, LLC Gilead Sciences, Inc. Transaction History

Gilman Hill Asset Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Oct 16, 2020	SELL	$62.1 - $78.08 $170,775 - $214,720	-2,750 Closed	0 $0
Q1 2020 Apr 22, 2020	SELL	$62.63 - $80.22 $78,287 - $100,275	-1,250 Reduced 31.25%	2,750 $206,000
Q3 2019 Oct 18, 2019	BUY	$62.51 - $69.0 $14,064 - $15,525	225 Added 5.96%	4,000 $254,000
Q2 2019 Jul 17, 2019	SELL	$61.87 - $69.38 $95,898 - $107,539	-1,550 Reduced 29.11%	3,775 $255,000
Q1 2019 Apr 24, 2019	BUY	$62.53 - $70.05 $332,972 - $373,016	5,325 New	5,325 $346,000
Q4 2018 Jan 29, 2019	SELL	$60.54 - $79.0 $216,430 - $282,425	-3,575 Closed	0 $0
Q3 2018 Oct 26, 2018	SELL	$71.28 - $78.92 $55,242 - $61,163	-775 Reduced 17.82%	3,575 $276,000
Q2 2018 Jul 23, 2018	BUY	$64.88 - $75.68 $282,228 - $329,208	4,350 New	4,350 $308,000

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Gilman Hill Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Gilman Hill Asset Management, LLC with notifications on news.